Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 5/20 | 0.70 |
| ▸ | FDPS | P14324 | 10/20 | 0.55 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.55 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1768907 | 1.00 | SMPD1 (0.70) | SMPD1FDPSGGPS1LPAR3LPAR1 | |
| SCHEMBL1287809 | 0.98 | SMPD1 (0.72) | SMPD1FDPSGGPS1LPAR3LPAR1 | |
| SCHEMBL1287808 | 0.84 | SMPD1 (0.58) | SMPD1FDPSGGPS1LPAR3LPAR1 | |
| SCHEMBL340325 | 0.81 | SMPD1 (0.55) | SMPD1FDPSGGPS1LPAR3LPAR1 | |
| SCHEMBL25174113 | 0.80 | SMPD1 (0.69) | SMPD1FDPSGGPS1LPAR3LPAR1 | |
| SCHEMBL11841083 | 0.80 | SMPD1 (0.69) | SMPD1FDPSGGPS1LPAR3LPAR1 | |
| SCHEMBL9659297 | 0.80 | SMPD1 (0.69) | SMPD1FDPSGGPS1LPAR3LPAR1 | |
| SCHEMBL9659055 | 0.80 | SMPD1 (0.69) | SMPD1FDPSGGPS1LPAR3LPAR1 | |
| SCHEMBL8567245 | 0.80 | SMPD1 (0.69) | SMPD1FDPSGGPS1LPAR3LPAR1 | |
| SCHEMBL6347597 | 0.80 | SMPD1 (0.69) | SMPD1FDPSGGPS1LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109200446-B | Medicine injection device for endoscope | 温州市中心医院 | 2024-05-14 | — | — | CN | claimed |
| WO-2021104777-A1 | ACTIVE SUBSTANCE COMBINATIONS OF UBIQUINOL AND ONE OR MORE EMULSIFIERS FROM THE GROUP OF PHOSPHATES AND SULFATES, AND COSMETIC OR DERMATOLOGICAL PREPARATIONS CONTAINING SUCH ACTIVE SUBSTANCE COMBINATIONS | BEIERSDORF AG (DE) | 2021-06-03 | — | — | WO | claimed |
| US-8323628-B2 | Long wear cosmetic composition | L'OREAL (FR) | 2012-12-04 | — | — | US | claimed |
| US-20120128606-A1 | Luna creme | IGIEBOR DAYO (US) | 2012-05-24 | — | — | US | claimed |
| US-8084507-B2 | Cosmetic O/W emulsion comprising 1,2-hexanediol | BEIERSDORF AG (DE) | 2011-12-27 | — | — | US | claimed |
| US-20110123472-A1 | LONG WEAR COSMETIC COMPOSITION | L'OREAL S.A. | 2011-05-26 | — | — | US | claimed |
| US-20070166257-A1 | Long wear cosmetic composition | L'OREAL S.A. (FR) | 2007-07-19 | — | — | US | claimed |
| EP-1592396-A4 | LONG WEAR COSMETIC COMPOSITION | OREAL (FR) | 2006-08-30 | — | — | EP | claimed |
| EP-1592396-A2 | LONG WEAR COSMETIC COMPOSITION | L'OREAL (FR) | 2005-11-09 | — | — | EP | claimed |
| WO-2004066918-A2 | LONG WEAR COSMETIC COMPOSITION | L'OREAL (FR) | 2004-08-12 | — | — | WO | claimed |
| US-12629327-B2 | Keratin-based hair straightening formulations, methods and systems | BEAUTY BIOLABS LLC (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3349782-B1 | PHARMACEUTICAL ASSOCIATION COMPRISING A GROWTH FACTOR RECEPTOR AGONIST CONJUGATED TO A BIOACTIVE CARRIER FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF | HISTIDE AG (CH) | 2026-02-11 | — | — | EP | disclosed |
| US-20260034033-A1 | MAKEUP COMPOSITION | L’ORÉAL (FR) | 2026-02-05 | — | — | US | disclosed |
| US-20250388633-A1 | PHARMACEUTICAL ASSOCIATION OF GROWTH FACTOR RECEPTOR AGONIST AND ADHESION PROTEIN INHIBITOR FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF | HISTIDE AG (CH) | 2025-12-25 | — | — | US | disclosed |
| US-20250352462-A1 | NOVEL COSMETIC OR DERMATOLOGICAL COMPOSITION CONTAINING A STRAIN OF LIVE PROBIOTIC BACTERIA | BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) | 2025-11-20 | — | — | US | disclosed |
| EP-0995427-A2 | O/W emulsions containing green tea extract | Dragoco Gerberding & Co Aktiengesellschaft (DE) | 2000-04-26 | — | — | EP | disclosed |
| US-6039961-A | SALICYLIC ACID COMPOUND WITH HYDROPHOBIC HYDROCARBON, HALIDE OR ANHYDRIDE | COLETICA (FR) | 2000-03-21 | — | — | US | disclosed |
| EP-0966268-A1 | CROSS-LINKED PLANT PROTEIN PARTICLES, IN PARTICULAR MICROPARTICLES OR NANOPARTICLES, PREPARATION METHOD AND COSMETIC, PHARMACEUTICAL OR FOOD COMPOSITIONS CONTAINING SAME | COLETICA (FR) | 1999-12-29 | — | — | EP | disclosed |
| US-5912016-A | ACRYLATING POLYFUNCTIONAL CROSSLINKING AGENTS FOR COSMETICS AND FOODS | COLETICA (FR) | 1999-06-15 | — | — | US | disclosed |
| WO-1999003450-A1 | CROSS-LINKED PLANT PROTEIN PARTICLES, IN PARTICULAR MICROPARTICLES OR NANOPARTICLES, PREPARATION METHOD AND COSMETIC, PHARMACEUTICAL OR FOOD COMPOSITIONS CONTAINING SAME | COLETICA (FR) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629327-B2 | Keratin-based hair straightening formulations, methods and systems | KRT18, HCN4, COL14A1 | SMPD1 1511/4885FDPS 4362/4885GGPS1 4768/4885 |
| US-20260034033-A1 | MAKEUP COMPOSITION | CUTA, FABP4, DEGS1 | SMPD1 288/4885FDPS 199/4885GGPS1 474/4885 |
| US-20250388633-A1 | PHARMACEUTICAL ASSOCIATION OF GROWTH FACTOR RECEPTOR AGONIST AND ADHESION PROTEIN INHIBITOR FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF | SELPLG, ROR1, VCAM1 | SMPD1 1161/4885FDPS 3286/4885GGPS1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.